Loading clinical trials...
Loading clinical trials...
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)
Conditions
Interventions
Bepirovirsen
Placebo
Locations
171
United States
GSK Investigational Site
Centreville, Alabama, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Ft. Pierce, Florida, United States
Start Date
December 6, 2022
Primary Completion Date
November 3, 2025
Completion Date
April 29, 2026
Last Updated
December 12, 2025
NCT07417553
NCT02932150
NCT06671093
NCT05853718
NCT06885710
NCT06906016
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions